$54.53
1.36% yesterday
Nasdaq, Oct 17, 10:09 pm CET
ISIN
US23282W6057
Symbol
CYTK

Cytokinetics, Incorporated Stock price

$54.53
-1.63 2.90% 1M
-13.40 19.73% 6M
-28.96 34.69% YTD
+19.15 54.13% 1Y
+18.76 52.45% 3Y
+43.19 380.86% 5Y
+51.27 1,572.70% 10Y
Nasdaq, Closing price Thu, Oct 17 2024
-0.75 1.36%
ISIN
US23282W6057
Symbol
CYTK
Sector
Industry

Key metrics

Market capitalization $6.42b
Enterprise Value $6.15b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1,964.55
P/S ratio (TTM) P/S ratio 2,049.84
P/B ratio (TTM) P/B ratio 59.04
Revenue growth (TTM) Revenue growth -68.51%
Revenue (TTM) Revenue $3.13m
EBIT (operating result TTM) EBIT $-506.09m
Free Cash Flow (TTM) Free Cash Flow $-401.27m
Cash position $1.06b
EPS (TTM) EPS $-5.37
P/E forward negative
P/S forward 620.52
EV/Sales forward 594.70
Short interest 22.50%
Show more

Is Cytokinetics, Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.

Cytokinetics, Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Cytokinetics, Incorporated forecast:

14x Buy
78%
4x Hold
22%

Analyst Opinions

18 Analysts have issued a Cytokinetics, Incorporated forecast:

Buy
78%
Hold
22%

Financial data from Cytokinetics, Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
3.13 3.13
69% 69%
100%
- Direct Costs 13 13
24% 24%
413%
-9.79 -9.79
2,076% 2,076%
-313%
- Selling and Administrative Expenses 168 168
7% 7%
5,355%
- Research and Development Expense 316 316
9% 9%
10,088%
-493 -493
5% 5%
-15,756%
- Depreciation and Amortization 13 13
24% 24%
413%
EBIT (Operating Income) EBIT -506 -506
5% 5%
-16,169%
Net Profit -545 -545
1% 1%
-17,421%

In millions USD.

Don't miss a Thing! We will send you all news about Cytokinetics, Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cytokinetics, Incorporated Stock News

Neutral
GlobeNewsWire
one day ago
NDA for Aficamten Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil,  and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to Begin in Q4 Global Commercial Launch Preparations Underway for First  Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign  “HCM Beyond The He...
Neutral
GlobeNewsWire
14 days ago
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2024 it granted stock options to purchase an aggregate of 88,653 shares of common stock and 57,558 restricted stock units (RSUs) that will be settled into shares of common stock upon vesting to 30 employees, whose employment commenced in September 2024, ...
Neutral
GlobeNewsWire
18 days ago
Responder Analyses Show Treatment with Aficamten Demonstrated Improvements on Multiple Assessments of Clinical Significance to Cardiologists
More Cytokinetics, Incorporated News

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Head office United States
CEO Robert Blum
Employees 423
Founded 1997
Website www.cytokinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today